Technical Data
MDR1 (Multi Drug Resistance Protein 1, ABC20, ATP Binding Cassette Subfamily B (MDR/TAP) Member 1, ABCB1, CD243, CLCS, GP170, P-Glycoprotein, P-gp, P Glycoprotein 1, PGY1)
P-glycoprotein, the product of the MDR1 (Multidrug Resistance 1) gene, is expressed in distinct non-malignant cells, typically cells with secretory and excretory functions. It is assumed to function as an ATP-dependent drug efflux pump with broad substrate specificity. The highest expression of the P-glycoprotein has been observed in kidney (proximal tubules), liver (bile canaliculi), adrenal gland and intestine suggesting that the primary role of P-glycoprotein is in the normal secretion of physiological metabolites and ingesting chemicals into bile, urine and the lumen of the intestinal tract. Elevated levels of P-glycoprotein have also been reported in the multidrug-resistant cell lines and in colon, endometrial, ovarian, breast tumors, sarcomas and lymphomas.

Suitable for use in Immunohistochemistry. Other applications not tested.

Recommended Dilution:
Immunohistochemistry: Frozen and formalin-fixed, paraffin-embedded tissue sections. Epitope retreival is required using citrate buffer. See protocol.
Optimal dilutions to be determined by the researcher.

Positive Control:

Expected Staining Pattern:

Storage and Stability:
May be stored at 4C for short-term only. For long-term storage and to avoid repeated freezing and thawing, add sterile glycerol (40-50%), aliquot and store at -20C. Aliquots are stable for at least 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
1ml4C (-20C Glycerol)Blue IceHumanMouse
Multi-Drug Resistant Chinese hamster cell line (CHrC5)
Tissue culture supernatant
Supplied as a liquid in PBS, pH 7.4, 1% BSA, 0.09% sodium azide.
Recognizes human Multi-Drug Resistance 1.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Juranka, P.F., et al., FASEB J. 3(14): 2583-2592 (1989). 2. Nooter, K., et al., Cytotechnology 12(1-3): 213-230 (1993). 3. Scheper, R.J., et al., Int. J. Cancer 42: 389-394 (1998). 4. Schinkel, A.H., et al., Cancer Res. 51: 2628-2635 (1991). 5. Tiirikainen, M.I., et al., Annals of Hematology 65: 124-130 (1992). 6. Goasquen, J.E., et al., Blood 81: 2394-2398 (1993). 7. Itsubo, M., et al., Cancer 73: 298-303 (1994). 8. Klimecki, W.T., et al., Blood 83: 2451-2458 (1994).